{
  "id": 3645790,
  "title": "China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial",
  "url": "https://urgent.news/2026/08/27/chinas-akeso-says-cancer-drug-beat-astrazenecas-imfinzi-in-phase-3-3645790",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T02:07:51.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/business/china-business/article/3365384/chinas-akeso-says-cancer-drug-beat-astrazenecas-imfinzi-phase-3-trial"
  },
  "original_language": "en",
  "account": null,
  "summary": "Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "SCMP Business",
        "title": "China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial",
        "url": "https://urgent.news/2026/08/27/chinas-akeso-says-cancer-drug-beat-astrazenecas-imfinzi-in-phase-3",
        "published": "2026-08-27T02:07:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}